ArticleFrontiers in immunology2025
SHP2 inhibition by SHP099 attenuates IL-6-driven osteoclastogenesis in growth plate injury.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pediatric physeal repair: from immune-angiogenic-osteogenic coupling to zonal biomimetic scaffolds.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Disruption of growth plate cartilage often leads to severe bone growth defects in children, necessitating novel therapeutic strategies. Following growth plate injury, an inflammatory response is rapidly initiated, resulting in the release of pro-inflammatory cytokines such as IL-6 into the injured tissue, which subsequently induce and enhance osteoclast generation and differentiation. This study investigates the role of SHP2 in regulating IL-6-driven osteoclastogenesis during growth plate injury repair. Methods: Tibial drill-hole injuries were induced in C57BL/6 mice (n=9), with SHP099 (30 mg/kg, intra-articular) administered to intervention groups and tissues were harvested for qPCR/histology. RAW 264.7 cells were treated with RANKL (100 ng/ml) ± IL-6 (100 ng/ml) ± SHP099 (15 µM). Osteoclast differentiation, expression level of pro-inflammatory cytokines and the associated signaling pathway were assessed via TRAP staining, Western blot, qPCR and ELISA. Results: SHP2/PTPN11, osteoclast markers (CTSK/OSCAR) and pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) was upregulated and could be inhibited by SHP099 at injury sites. IL-6 enhanced p-SHP2/p-TAK1 expression, osteoclastogenesis and inflammatory response in vitro, while SHP099 effectively reduced osteoclast numbers, downregulating CTSK/OSCAR and pro-inflammatory cytokines (IL-6, IL-1β, TNF-α). Furthermore, the NF-κB pathway remained unaffected by SHP099, indicating a distinct signaling mechanism through which SHP2 regulates osteoclastogenesis. Discussion: Our findings underscore the pivotal role of SHP2 as a downstream signaling molecule of IL-6 in mediating inflammatory responses during bone repair, suggesting that SHP2 inhibition may present a novel therapeutic approach to prevent pathological bone remodeling and enhance recovery following growth plate injuries. Future investigations should focus on the translational potential of SHP2 inhibitors in pediatric orthopedics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.